awmsg logo



delta-9-tetrahydrocannabinol/cannabidiol (Sativex®)


Reference No. 644

Publication date:
13/08/2014

Appraisal information

delta-9-tetrahydrocannabinol/cannabidiol (Sativex®) 2.7 mg/2.5mg oromucosal spray


Company: Bayer Healthcare Pharmaceuticals
BNF category: Musculoskeletal and joint diseases
NMG meeting date: 18/06/2014
AWMSG meeting date: 16/07/2014
   
   
Submission Type: Full Submission
Status: Recommended
Advice No: 1814
Ministerial ratification: 13/08/2014

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Delta-9-tetrahydrocannabinol/cannabidiol (Sativex®) is recommended as an option for use within NHS Wales as treatment for symptom improvement in adult patients with moderate to severe spasticity due to multiple sclerosis who have not responded adequately to other anti-spasticity medication and who demonstrate clinically significant improvement in spasticity related symptoms during an initial trial of therapy.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download